Journal article icon

Journal article

Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020–2021

Abstract:
Rapid development and successful use of vaccines against SARS-CoV-2 might hold the key to curb the ongoing pandemic of COVID-19. Emergence of vaccine-evasive SARS-CoV-2 variants of concern (VOCs) has posed a new challenge to vaccine design and development. One urgent need is to determine what types of variant-specific and bivalent vaccines should be developed. Here, we compared homotypic and heterotypic protection against SARS-CoV-2 infection of hamsters with monovalent and bivalent whole-virion inactivated vaccines derived from representative VOCs. In addition to the ancestral SARS-CoV-2 Wuhan strain, Delta (B.1.617.2; δ) and Theta (P.3; θ) variants were used in vaccine preparation. Additional VOCs including Omicron (B.1.1.529) and Alpha (B.1.1.7) variants were employed in the challenge experiment. Consistent with previous findings, Omicron variant exhibited the highest degree of immune evasion, rendering all different forms of inactivated vaccines substantially less efficacious. Notably, monovalent and bivalent Delta variant-specific inactivated vaccines provided optimal protection against challenge with Delta variant. Yet, some cross-variant protection against Omicron and Alpha variants was seen with all monovalent and bivalent inactivated vaccines tested. Taken together, our findings support the notion that an optimal next-generation inactivated vaccine against SARS-CoV-2 should contain the predominant VOC in circulation. Further investigations are underway to test whether a bivalent vaccine for Delta and Omicron variants can serve this purpose.published_or_final_versio
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.3201/eid2803.211993
Publication website:
http://hub.hku.hk/bitstream/10722/315207/1/content.pdf

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0690-0275
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-5352-6071
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8929-2200
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0003-2859-9150


Publisher:
Centers for Disease Control and Prevention
Journal:
Emerging Infectious Diseases More from this journal
Volume:
28
Issue:
3
Pages:
709-712
Publication date:
2021-12-28
DOI:
EISSN:
1080-6059
ISSN:
1080-6040


Language:
English
Keywords:
Pubs id:
1242217
Local pid:
pubs:1242217
Source identifiers:
W4200048811
Deposit date:
2026-04-09
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP